Pentraxin-3 vs C-reactive protein and other prognostic biomarkers in acute coronary syndrome: A substudy of the Platelet Inhibition and Patients Outcomes (PLATO) trial

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: onr:"swepub:oai:DiVA.org:uu-401234" > Pentraxin-3 vs C-re...

1 of 1
Previous record
Next record
To hitlist

Details
MARC

Kontny, Frederic (author)

Pentraxin-3 vs C-reactive protein and other prognostic biomarkers in acute coronary syndrome : A substudy of the Platelet Inhibition and Patients Outcomes (PLATO) trial

Article/chapterEnglish2020

Publisher, publication year, extent ...

2019-04-24
Oxford University Press (OUP),2020
printrdacarrier

Numbers

LIBRIS-ID:oai:DiVA.org:uu-401234
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-401234URI
https://doi.org/10.1177/2048872619846334DOI

Supplementary language notes

Language:English
Summary in:English

Part of subdatabase

SwePubSwePub

Classification

Subject category:ref swepub-contenttype
Subject category:art swepub-publicationtype

Notes

AIMS: We investigated the dynamics, associations with patient characteristics, other biomarkers, and clinical outcomes of pentraxin 3 in acute coronary syndrome.METHODS AND RESULTS: In multivariate analyses, pentraxin 3 measured in 5154 patients randomised in the Platelet Inhibition and Patients Outcomes (PLATO) trial (NCT00391872) was compared with leukocytes, high-sensitivity C-reactive protein, interleukin-6, cystatin C, N-terminal prohormone brain natriuretic peptide, high-sensitivity troponin T and growth differentiation factor 15 concerning prediction of clinical outcome. Pentraxin 3 peaked earlier than high-sensitivity C-reactive protein and was more strongly correlated with N-terminal prohormone brain natriuretic peptide and high-sensitivity troponin T than with high-sensitivity C-reactive protein. The frequency of cardiovascular death, spontaneous myocardial infarction or stroke by quartiles of pentraxin 3 at admission was 6.1%, 7.3%, 9.7% and 10.7%, respectively ( p<0.0001). The hazard ratio per 50% increase of pentraxin 3 was 1.13 (95% confidence interval: 1.07-1.19), p<0.0001. This association remained significant after stepwise adjustments for leukocytes/high-sensitivity C-reactive protein (1.09 (1.02-1.15)), p=0.009, interleukin-6 (1.07 (1.01-1.14)), p=0.026, and cystatin C (1.07 (1.00-1.13)), p=0.044, but not after adjustment for N-terminal prohormone brain natriuretic peptide, high-sensitivity troponin T and growth differentiation factor 15. Admission pentraxin 3 was also associated with several of the individual endpoint components (cardiovascular death/spontaneous myocardial infarction; p=0.008, cardiovascular death; p=0.026, and spontaneous myocardial infarction; p=0.017), but not with stroke. Pentraxin 3 measured in the chronic phase (i.e. at one month) was still predictive of the composite endpoint in univariate analysis (1.12 (1.04-1.20) per 50% increase) p=0.0024, but not after adjustment for the other biomarkers.CONCLUSION: Admission level of pentraxin 3 is a modestly stronger predictor than high-sensitivity C-reactive protein and interleukin-6, but not than N-terminal prohormone brain natriuretic peptide or high-sensitivity troponin T, concerning cardiovascular outcome in acute coronary syndrome. Pentraxin 3 is more strongly correlated with N-terminal prohormone brain natriuretic peptide and high-sensitivity troponin T than with high-sensitivity C-reactive protein.

Subject headings and genre

MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Kardiologi hsv//swe
MEDICAL AND HEALTH SCIENCES Clinical Medicine Cardiac and Cardiovascular Systems hsv//eng
C-reactive protein
Pentraxin 3
acute coronary syndrome
adverse clinical outcome
biomarkers
prognosis

Added entries (persons, corporate bodies, meetings, titles ...)

Andersen, Thomas (author)
Ueland, Thor (author)
Åkerblom, Axel,1977-Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi(Swepub:uu)axeak985 (author)
Ghukasyan Lakic, TatevikUppsala universitet,Uppsala kliniska forskningscentrum (UCR)(Swepub:uu)tatgh570 (author)
Michelsen, Annika E. (author)
Aukrust, Pål (author)
Bertilsson, MariaUppsala universitet,Uppsala kliniska forskningscentrum (UCR)(Swepub:uu)marbe354 (author)
Becker, Richard C. (author)
Himmelmann, Anders (author)
James, Stefan K.,1964-Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi(Swepub:uu)stjam367 (author)
Siegbahn, Agneta,1947-Uppsala universitet,Kardiologi,Klinisk kemi(Swepub:uu)agsie424 (author)
Storey, Robert F. (author)
Wallentin, Lars,1943-Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi(Swepub:uu)larswall (author)
Uppsala universitetUppsala kliniska forskningscentrum (UCR) (creator_code:org_t)

Related titles

In:European Heart Journal: Oxford University Press (OUP)9:4, s. 313-3222048-87262048-8734

Internet link

Find in a library

European Heart Journal (Search for host publication in LIBRIS)

To the university's database

1 of 1
Previous record
Next record
To hitlist

Find more in SwePub

By the author/editor: Kontny, Frederic; Andersen, Thomas; Ueland, Thor; Åkerblom, Axel, ...; Ghukasyan Lakic, ...; Michelsen, Annik ...; show more...; Aukrust, Pål; Bertilsson, Mari ...; Becker, Richard ...; Himmelmann, Ande ...; James, Stefan K. ...; Siegbahn, Agneta ...; Storey, Robert F ...; Wallentin, Lars, ...; show less...

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Clinical Medicin ...; and Cardiac and Card ...

Articles in the publication: European Heart J ...

By the university: Uppsala University

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se